# Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

> **NCT00129168** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kanisa Pharmaceuticals** · enrollment: 100 (estimated)

## Conditions studied

- Leukemia, Myeloid

## Interventions

- **DRUG:** Zosuquidar
- **DRUG:** Daunorubicin
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT00129168
- **Lead sponsor:** Kanisa Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2008-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129168, "Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00129168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*